Neurogene Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Neurogene Inc. (NGNE) reported Cash and Cash Equivalents, Period Increase (Decrease) of $14.58 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-08
- Neurogene Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $14.58M.
- Neurogene Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $4.93M.
- Neurogene Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $19.96M, a 68.70% decline year-over-year.
- Neurogene Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $6.23M.
- Neurogene Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $19.73M.
- Neurogene Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$7.22M, a 129.35% decline from fiscal 2015.
- Neurogene Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $24.62M, a 531.28% increase from fiscal 2014.
- Neurogene Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $3.90M, a 56.69% decline from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 123 month |
|---|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | $14.58M 10-Q · filed 2018-05-08 | $19.50M derived: sum of 2 quarters · filed 2018-05-08 | $39.46M derived: sum of 3 quarters · filed 2018-05-08 | $45.69M derived: sum of 4 quarters · filed 2018-05-08 | |||||
| 2017-12-31 | $4.93M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $24.89M derived: sum of 2 quarters · filed 2018-03-12 | $31.12M derived: sum of 3 quarters · filed 2018-03-12 | $19.73M 10-K · filed 2018-03-12 | |||||
| 2017-09-30 | $19.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $26.19M derived: sum of 2 quarters · filed 2017-11-08 | $14.80M 10-Q · filed 2017-11-08 | -$39.12M derived: sum of 4 quarters · filed 2018-05-08 | |||||
| 2017-06-30 | $6.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$5.15M 10-Q · filed 2017-08-08 | -$59.08M derived: sum of 3 quarters · filed 2018-05-08 | $4.68M derived: sum of 4 quarters · filed 2018-05-08 | |||||
| 2017-03-31 | -$11.38M 10-Q · filed 2018-05-08 | -$65.31M derived: sum of 2 quarters · filed 2018-05-08 | -$1.55M derived: sum of 3 quarters · filed 2018-05-08 | -$14.78M derived: sum of 4 quarters · filed 2018-05-08 | |||||
| 2016-12-31 | -$53.92M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $9.83M derived: sum of 2 quarters · filed 2018-03-12 | -$3.39M derived: sum of 3 quarters · filed 2018-03-12 | -$7.22M 10-K · filed 2018-03-12 | |||||
| 2016-09-30 | $63.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $50.53M derived: sum of 2 quarters · filed 2017-11-08 | $46.70M 10-Q · filed 2017-11-08 | -$23.15M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2016-06-30 | -$13.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$17.06M 10-Q · filed 2017-08-08 | -$86.90M derived: sum of 3 quarters · filed 2018-03-12 | $7.55M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2016-03-31 | -$3.83M 10-Q · filed 2017-05-09 | -$73.68M derived: sum of 2 quarters · filed 2018-03-12 | $20.77M derived: sum of 3 quarters · filed 2018-03-12 | $21.41M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2015-12-31 | -$69.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $24.61M derived: sum of 2 quarters · filed 2018-03-12 | $25.24M derived: sum of 3 quarters · filed 2018-03-12 | $24.62M 10-K · filed 2018-03-12 | |||||
| 2015-09-30 | $94.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $95.09M derived: sum of 2 quarters · filed 2016-11-09 | $94.47M 10-Q · filed 2016-11-09 | $93.50M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2015-06-30 | $633.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $10.00K 10-Q · filed 2016-08-04 | -$953.00K derived: sum of 3 quarters · filed 2017-03-09 | -$2.98M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2015-03-31 | -$623.00K 10-Q · filed 2016-05-10 | -$1.59M derived: sum of 2 quarters · filed 2017-03-09 | -$3.61M derived: sum of 3 quarters · filed 2017-03-09 | -$38.64M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2014-12-31 | -$963.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | -$2.99M derived: sum of 2 quarters · filed 2017-03-09 | -$38.01M derived: sum of 3 quarters · filed 2017-03-09 | $3.90M 10-K · filed 2017-03-09 | $3.90M 10-K · filed 2015-03-16 | ||||
| 2014-09-30 | -$2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$37.05M derived: sum of 2 quarters · filed 2015-11-10 | $4.86M 10-Q · filed 2015-11-10 | $4.86M 10-Q · filed 2014-11-04 | $437.00 derived: sum of 4 quarters · filed 2016-03-14 | ||||
| 2014-06-30 | -$35.02M 10-Q · filed 2014-08-11 | $6.89M 10-Q · filed 2015-08-06 | $6.89M 10-Q · filed 2014-08-11 | $2.03M derived: sum of 3 quarters · filed 2016-03-14 | $305.69K derived: sum of 4 quarters · filed 2016-03-14 | ||||
| 2014-03-31 | $41.91M 10-Q · filed 2015-05-12 | $41.91M 10-Q · filed 2014-05-13 | $37.05M derived: sum of 2 quarters · filed 2016-03-14 | $35.33M derived: sum of 3 quarters · filed 2016-03-14 | $33.90M derived: sum of 4 quarters · filed 2016-03-14 | $52.92M 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | -$4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$6.58M derived: sum of 2 quarters · filed 2016-03-14 | -$8.01M derived: sum of 3 quarters · filed 2016-03-14 | $9.01M 10-K · filed 2016-03-14 | $9.01M 10-K · filed 2015-03-16 | ||||
| 2013-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | -$3.15M derived: sum of 2 quarters · filed 2014-11-04 | $13.87M 10-Q · filed 2014-11-04 | ||||||
| 2013-06-30 | -$1.43M 10-Q · filed 2014-08-11 | $15.59M 10-Q · filed 2014-08-11 | |||||||
| 2013-03-31 | $17.02M 10-Q · filed 2014-05-13 | ||||||||
| 2012-12-31 | -$7.24M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |